Novo Nordisk Considers Early Launch of Weight-Loss Jab Wegovy in India, Reuters Says, Citing Sources

Dow Jones

04-08

--Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources.

--The Danish drug maker of diabetes and obesity treatments Ozempic and Wegovy looks to potentially sell Wegovy in India in the next few months, earlier than its initial 2026 target, Reuters reports.

--The company declined to comment to Reuters.

Full story: https://bit.ly/422dUrF

Write to Helena Smolak at helena.smolak@wsj.com

(END) Dow Jones Newswires

April 07, 2025 12:51 ET (16:51 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2525024957"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525024957\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2525024957?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 00:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525024957","market":"hk","top_or_hot":-1,"title":"Novo Nordisk Considers Early Launch of Weight-Loss Jab Wegovy in India, Reuters Says, Citing Sources","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  --Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources. \n</p>\n<p>\n  --The Danish drug maker of diabetes and obesity treatments Ozempic and Wegovy looks to potentially sell Wegovy in India in the next few months, earlier than its initial 2026 target, Reuters reports. \n</p>\n<p>\n  --The company declined to comment to Reuters. \n</p>\n<pre>\n \n</pre>\n<p>\n  Full story: https://bit.ly/422dUrF \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Helena Smolak at helena.smolak@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 07, 2025 12:51 ET (16:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Considers Early Launch of Weight-Loss Jab Wegovy in India, Reuters Says, Citing Sources</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Considers Early Launch of Weight-Loss Jab Wegovy in India, Reuters Says, Citing Sources\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-08 00:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  --Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources. \n</p>\n<p>\n  --The Danish drug maker of diabetes and obesity treatments Ozempic and Wegovy looks to potentially sell Wegovy in India in the next few months, earlier than its initial 2026 target, Reuters reports. \n</p>\n<p>\n  --The company declined to comment to Reuters. \n</p>\n<pre>\n \n</pre>\n<p>\n  Full story: https://bit.ly/422dUrF \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Helena Smolak at helena.smolak@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 07, 2025 12:51 ET (16:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文藝復興科技持倉","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2525024957","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525024957","pubTimestamp":1744044660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"--Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources.--The Danish drug maker of diabetes and obesity treatments Ozempic and Wegovy looks to potentially sell Wegovy in India in the next few months, earlier than its initial 2026 target, Reuters reports.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股","NVO":"诺和诺德","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"路透社援引消息人士的话称，诺和诺德考虑在印度提前推出减肥疫苗Wegovy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"--Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources. \n\n\n  --The Danish drug maker of diabetes and obesity treatments Ozempic and Wegovy looks to potentially sell Wegovy in India in the next few months, earlier than its initial 2026 target, Reuters reports. \n\n\n  --The company declined to comment to Reuters. \n\n\n \n\n\n  Full story: https://bit.ly/422dUrF \n\n\n \n\n\n  Write to Helena Smolak at helena.smolak@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 12:51 ET (16:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}